78.75EUR-0.25%Mkt Cap: 19.32B EURP/E: —Last update: 2026-05-14
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also devel…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG0.04
P/B1.03
P/S6.89
EV/EBITDA-4.97
EV/Revenue2.11
EPS (TTM)-5.07
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-2.22%
FCF Margin-15.26%
Operating CF456.00M EUR
CapEx (TTM)749.00M EUR
Net Debt/EBITDA11.25
Net Debt-13.40B EUR
Technical
SMA 5081.32 (-3.2%)
SMA 20086.97 (-9.5%)
Beta1.37
S&P 52W Chg24.23%
Avg Vol (30d)54.92K
Avg Vol (10d)96.55K
Technical Indicators
RSI (14)39.6
MACD-1.1773
MACD Signal-0.1334
MACD Hist.-1.0439
BB Upper95.41 EUR
BB Middle85.34 EUR
BB Lower75.28 EUR
BB Width23.58%
ATR (14)3.265 EUR
Vol Ratio (20d)0.48x
52W Range
68.3025% of range110.90
52W High110.90 EUR
52W Low68.30 EUR
Profitability
Gross Margin77.64%
EBITDA Margin-42.47%
Profit Margin-39.59%
Oper. Margin-576.63%
ROE-5.91%
ROA-5.17%
Revenue Growth-35.40%
Earnings Growth—
Balance Sheet
Debt/Equity0.01
Current Ratio8.80
Quick Ratio8.11
Book Value/Sh73.94 EUR
Cash/Share54.20 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 2, 2022
Pay Date—
Ownership
Shares Out.252.88M
Float109.30M
Insiders57.42%
Institutions19.74%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap19.32B EUR
Enterprise Value5.92B EUR
Revenue (TTM)2.81B EUR
Gross Profit2.23B EUR
Net Income (TTM)-1.14B EUR
Revenue/Share11.45 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7.8K
Last Price78.75 EUR
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINUS09075V1026